Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Recombinant Human Epidermal Growth Factor-Loaded Liposomes and Transferosomes for Dermal Delivery: Development, Characterization, and Cytotoxicity Evaluation Publisher Pubmed



Doustvaghe YK1 ; Haeri A2, 3 ; Sisakht MM4, 5 ; Amirkhani MA6 ; Vatanpour H1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pharmacology and Toxicology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Department of Pharmaceutics and Pharmaceutical Nanotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. Protein Technology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  4. 4. Faculty of Pharmacy, Biotechnology Research Center, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Stem Cell and Regenerative Medicine Innovation Center, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran

Source: Drug Development Research Published:2024


Abstract

Recombinant human epidermal growth factor (rhEGF) is widely utilized as an antiaging compound in wound-healing therapies and cosmetic purposes. However, topical administration of rhEGF has limited treatment outcomes because of its poor percutaneous penetration and rapid proteinase degradation. To overcome these obstacles, this study aims to develop and characterize rhEGF-containing conventional liposomes (rhEGF-CLs) and transferosomes (rhEGF-TFs) as efficient dermal carriers. Physicochemical characterization such as particle size, zeta potential (ZP), morphology, encapsulation efficiency (EE%), and release properties of nanocarriers as well as in vitro cytotoxicity in human dermal fibroblast (HDF) and human embryonic kidney (HEK293) cell lines were investigated. rhEGF-TFs at the rhEGF concentration ranging from 0.05 to 1.0 μg/mL were chosen as the optimum formulation due to the desired release profile, acceptable EE%, optimal cell proliferation, and minimal cytotoxicity compared to the control and free rhEGF. However, higher concentrations caused a decrease in cell viability. The ratio 20:80 of Tween 80 to lipid was optimal for rhEGF-TFs-2, which had an average diameter of 233.23 ± 2.64 nm, polydispersity index of 0.33 ± 0.05, ZP of −15.46 ± 0.29 mV, and EE% of 60.50 ± 1.91. The formulations remained stable at 5°C for at least 1 month. TEM and SEM microscopy revealed that rhEGF-TFs-2 had a regular shape and unilamellar structure. In vitro drug release studies confirmed the superiority of rhEGF-TFs-2 in terms of optimal cumulative release of rhEGF approximately 82% within 24 h. Franz diffusion cell study showed higher rhEGF-TFs-2 skin permeation compared to free rhEGF solution. Taken together, we concluded that rhEGF-TFs can be used as a promising formulation for wound healing and skin regeneration products. © 2024 Wiley Periodicals LLC.
Related Docs
1. New Concepts in Wound Targeting Through Liposome-Based Nanocarriers (Lbns), Journal of Drug Delivery Science and Technology (2022)
2. Exosomes As a Next-Generation Drug Delivery System: An Update on Drug Loading Approaches, Characterization, and Clinical Application Challenges, Acta Biomaterialia (2020)
Experts (# of related papers)
Shahram Rabbani (1)
Alireza Partoazar (1)